Novartis reported sales for its Alcon eye care business of $1.5 billion in the second quarter, up by 3 percent versus the same period a year earlier. Surgical sales grew by 3 percent, driven by the strong increase of cataract consumables and the return to growth globally of intraocular lenses. ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
To continue reading this article register now.